From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders
- 1 June 2013
- journal article
- review article
- Published by Elsevier BV in Biological Psychiatry
- Vol. 73 (12), 1172-1179
- https://doi.org/10.1016/j.biopsych.2013.03.032
Abstract
No abstract availableThis publication has 96 references indexed in Scilit:
- Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent MannerNeuron, 2012
- Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampusPsychopharmacology, 2012
- Riluzole and gabapentinoids activate glutamate transporters to facilitate glutamate-induced glutamate release from cultured astrocytesEuropean Journal of Pharmacology, 2012
- Heterogeneity of Astrocytic Form and FunctionMethods in Molecular Biology, 2011
- Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in micePsychopharmacology, 2011
- Glial and glutamatergic markers in depression, alcoholism, and their comorbidityJournal of Affective Disorders, 2010
- Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine SeekingBiological Psychiatry, 2010
- Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like BehaviorsBiological Psychiatry, 2008
- Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouseNeuroscience, 2008
- Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1European Journal of Pharmacology, 2008